Hutchmed announces licensing agreement with GSK for KRAS-EGFR therapy
Hutchmed said it has announced a licensing agreement with GSK for a KRAS-EGFR antibody conjugate cancer therapy.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.